Novo Nordisk's Ultra-Fast Acting Insulin Cleared For Pediatric Use In EU
Executive Summary
A market opportunity has just opened up for Novo Nordisk’s ultra-fast acting mealtime insulin, Fiasp: its indications have just been extended to include younger EU patients who are aged more than one year.